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Abstract
Background and Aims: Commercial plasma donation was introduced in China in the
1970s. Cases of non-A, non-B hepatitis (hepatitis C) continued to occur, with multiple
outbreaks among plasma donors in Guan county, Hebei province between 1972 and 1990.
The outcomes of hepatitis C virus (HCV) infection in these paid plasma donors from six
villages of Guan county were followed up for 12–19 years.
Methods: A total of 402 plasma donors with HCV infection were enrolled since anti-
HCV-positive in 1991 or 1998. Follow up was maintained until death or the end of the
observation period. No antiviral treatment was applied during the period of infection.
Results: Follow up was lost in 23 cases. After a 12–19-year follow up, 31 donors died,
with the cause of death directly related to liver disease in 15 cases, and an overall mortality
of 8.18% (31/379). The incidence of liver cirrhosis was 10.03%, and hepatocellular carci-
noma (HCC) was 2.90%. The rate of viral spontaneous clearing was 20.32% (77/379), and
13.69% (23/168) in males and 25.59% (54/211) in females. In May 2010, detections were
performed in 348 cases. Abnormality of liver function was related to HCV viremia. Sex and
alcohol intake impacted the outcome of HCV infection. There was no correlation between
the viral spontaneous clearance with age of infection and genotype.
Conclusions: This area has a high rate of chronicity in HCV infection due to plasma
donation. Twenty-five years after virus infection, liver cirrhosis or HCC developed in
one-tenth of patients, with an overall mortality of 8.18%.
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Introduction
Hepatitis C virus (HCV) infection is rated by the World Health
Organization as a global health problem, based on its prevalence;
the high rate of chronicity; severe complications, such as cirrhosis
and hepatocellular carcinoma (HCC); as well as the high costs of
antiviral therapy and liver transplantation.1–3 Screening measures
by transfusion organizations, as well as preventive measures,
have indeed led to a decreasing incidence of HCV infections.
However, the prevalence of fully-developed illnesses and subse-
quent mortality caused by HCV are rising.3 An evaluation of the
risk of progression to cirrhosis and hepatocellular carcinoma
(HCC) is very important, not only for the general welfare of
society, but also for the individual patient. In order determine the
appropriate therapy, studies of the natural course of the disease
are necessary.
Three types of studies, prospective, retrospective, and
retrospective–prospective, were carried out to determine the
outcomes of chronic HCV infection. The combined population
data indicate that the disease progresses slowly over 30 years.
Approximately 20% of infected individuals will progress to fibro-
sis and cirrhosis. Of these, 20% will progress to HCC. The possi-
bility of progression increases with alcohol intake, male sex, and
age over 40 years at infection, but appears to be independent of
genotype or viral load.4
Existing studies differ widely in design, with the particular
concern that specialized clinics, where some of these studies took
place, are more likely to see patients with advanced chronic liver
disease and less likely to see those without any symptoms. Inter-
national consensus conferences have therefore called for further
prospective studies, as well documented populations, indicating
that natural history studies should begin with the onset of HCV
infections. Of particular interest are the rare instances in which
infection begins at a known time.5
Several studies have followed patient cohorts with a known
onset of infection.5–10 Within the first 20 years after infection,
doi:10.1111/j.1440-1746.2011.06880.x
526 Journal of Gastroenterology and Hepatology 27 (2012) 526–532
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
hepatitis C follows a relatively benign course. Some variability has
been shown, but overall between 5% and 25% of patients have
spontaneous viral clearance, and the majority of adults have per-
sistent viremia without clinically demonstrable liver disease.5–9
However, the natural course of HCV infection in plasma donors
with a known onset of infection remains poorly understood, espe-
cially in China. In Austria, a 31-year follow up of 439 paid plasma
donors who received hepatitis C infection showed that advanced
liver disease developed in one-third of patients, with an overall
mortality of 7%.10
Between 1972 and 1990, several outbreaks of hepatitis non-A,
non-B virus infection linked to plasma donation occurred at plas-
mapheresis centers in Guan county, Hebei province. These donors
were followed for 12–19 years after initial documentation of HCV
infection. The study investigated the outcomes of HCV infection in
these plasma donors from six villages of Guan country. This
12–19-year follow-up helps us to further understand the natural
outcome of chronic hepatitis C and to clarify the long-term
outcome of chronic hepatitis C in infected Chinese patients.
Methods
Patients
Commercial plasma donation was introduced in China in the
1970s. Prior to each donation, the donors were required to have
normal alanine aminotransferase (ALT), and no HBV infection
was detected. Nevertheless, cases of non-A, non-B hepatitis con-
tinued to arise, and multiple outbreaks with over 500 infected
donors occurred in Guan county, Hebei province between 1972
and 1990.
The return of blood cells is thought to be through common
transfusion lines contaminated with HCV. The cause of these out-
breaks was believed to be related to return of red cells to donors
through contaminated transfusion lines.
After hepatitis C testing became available, donors from five
villages were tested for hepatitis C antibody (anti-HCV) in 1991,
and donors from the sixth village were tested for anti-HCV in
1998. Of the 769 registered, paid donors, 704 came back for
anti-HCV testing, and 402 (57.1%) of these tested positive.
Because the donors were required to have normal ALT levels
before donation, the date of the first test showing an increase in
ALT levels was considered as the time of infection. For the donors
with normal ALT levels, the lattermost plasma donation time was
considered as the time of infection. Donors who tested positive for
anti-HCV were invited to return for follow-up assessment every
5–6 years, between 1991 and 2008, and once a year thereafter. At
each visit, the donors were evaluated, and blood was tested for
anti-HCV and ALT. HCV-RNA was tested during follow-up visits
in 2002, 2009, and 2010. Follow up was maintained until death or
the end of the observation period (May 2010). Follow up was lost
for 23 donors because of change of residence and/or telephone
number. No antiviral treatment was applied during the period of
infection. Twelve to 19 years later, in May 2010, anti-HCV, HCV-
RNA, biochemistry, and ultrasonography were detected in 348
donors of this cohort; liver stiffness measures were performed in
183 donors.
This study was approved by the Ethical Committee of Human
Experimentation at Peking University People’s Hospital (Beijing,
China), and was in accordance with the 1975 Declaration of Hel-
sinki. The plasma donors were enrolled after giving their written,
informed consent for the follow-up study.
Biochemical tests
Three milliliters of peripheral vein blood was collected for the
biochemical detection. ALT, aspartate aminotransferase (AST),
g-glutamyltransferase (g-GT), alkaline phosphatase, total biliru-
bin, direct bilirubin, total protein, and albumin were tested by an
automated biochemical analyzer (7600; HITACHI, Tokyo, Japan).
Virology tests
Tests for anti-HCV were carried out using enzyme immunoassay
(Chiron, Emeryville, CA, USA) between 1991 and 2005, and a
chemiluminescent microparticle immunoassay (Architect; Abbott
Laboratories, Chicago, IL, USA) after 2005. HCV-RNA was quan-
titated with Cobas Ampliprep/Cobas Taqman HCV assay (Roche
Molecular Diagnostics, Branchburg, NJ, USA) that has a lower
limit of detection of 15 IU/mL. HCV was genotyped with a restric-
tion fragment length polymorphism.11 Hepatitis B virus surface
antigen (HBsAg) was detected by enzyme immunoassay (Abbott
Laboratories, USA), and anti-HIV by enzyme immunoassay
(BioMérieux, Boxtel, the Netherlands).
Risk factors for HCV chronicity
All data of risk factors for HCV chronicity were collected by using
special questionnaires relating to sex, age, age at infection, symp-
toms, and alcohol consumption.
Ultrasonography evaluation
On the same day, the ultrasonography evaluation was carried out
by two experienced gastroenterologists specifically trained in
ultrasonography; the gastroenterologists were unaware of the
clinical history and biochemical test results. Commercially-
available real-time ultrasonography equipment (Logic Book; GE
Medical Systems, Milwaukee, WI, USA) was utilized. Cirrhosis
was diagnosed by ultrasound, based on a quantitative scoring
system derived from the appearance of the liver surface, liver
parenchymal texture, intrahepatic blood vessel size, and splenic
size.12
Liver stiffness measured by transient
elastography
In 183 donors, non-invasive evaluation of liver fibrosis was per-
formed using liver stiffness measurement (FibroScan [FS]; Echo-
sens, Paris, France). The tip of the probe transducer was placed on
the skin between the rib bones and the level of the right lobe of the
liver. The measurement depth was between 25 and 65 mm below
the skin surface. Ten measurements were performed, with success
rates of at least 60%. The results were expressed in kilopascals
(kPa). The median value was taken as the representative value. For
this evaluation, fibrosis assessment was performed using a pub-
lished cut-off.13 Significant fibrosis (F = 2) was defined when the
FS value was between 7.2 and 9.5 kPa, severe fibrosis (F = 3)
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when the FS value was between 9.6 and 12.5 kPa, and cirrhosis
(F = 4) when the FS value was > 12.5 kPa. FS measurements with
an interquartile range higher than 40% were excluded. Eight of the
initial 183 patients were excluded because of invalid liver stiffness
measurements or high interquartile range values.
Diagnostic criterion
The diagnoses of HCV infection in the present study were catego-
rized as: (i) HCV spontaneous clearance (serum HCV-RNA unde-
tectable); (ii) chronic HCV infection, chronic viremia (serum
HCV-RNA positive);14 (iii) liver cirrhosis: ultrasonography diag-
nosis or clinical diagnosis in the presence of palpable liver with
consistency grade III–IV and blunt margins or caput medusae,
esophageal varices, ascites; and (iv) HCC: liver nodules found on
ultrasound surveillance, and typical of HCC, found on computed
tomography or magnetic resonance scanning scanning.15
The diagnostic criteria for fatty change in the liver by ultra-
sonography were as follows:16 (i) a diffuse hyperechoic echotex-
ture (bright liver); (ii) an increased liver echotexture compared to
the kidney or spleen; (iii) vascular blurring; and (iv) deep attenu-
ation. Specifically, comparison with a non-affected parenchymal
organ (kidney or spleen) is encouraged, and two additional fea-
tures are sought: blurring of hepatic vessels and deep attenuation
of the ultrasound signal.
Statistical analysis
Results are expressed as means SE. Comparison of quantitative
data was made using the Student’s t-test. Qualitative data were
analyzed using the c2-test and odds ratio (OR). A P-value of less
than 0.05 was considered to indicate a statistically-significant dif-
ference. The statistical software package used was SPSS 13.0 for
Windows (SPSS, Chicago, IL, USA).
Results
Relative benign outcome of HCV infection in
Chinese paid plasma donors
Of the 379 patients enrolled in this study in 1991 or 1998 and
followed up for 12–19 years, 31 died (8.18%, Fig. 1). Of these 31
patients, 12 were males and 19 were females, with a mean age at
death of 63.2  8.3 years. Death was directly related to liver dis-
eases in 15 plasma donors. Five died of liver cirrhosis, and 10 died
of HCC. In the 15 donors, HCV-RNA was positive, with mean
viral load of 5.8 log10 IU/mL; 13 were HCV genotype 1b, and two
were 2a. The HCV-related mortality was relatively low (3.96%).
Other causes of death were cerebral hemorrhage (n = 8), cerebral
infarction (1), lung diseases (2), heart failure (1), myocardial inf-
arction (1), bone cancer (1), organophosphate poisoning (1), and
struck by lightning (1). Thirty eight (10.03%) progressed to liver
cirrhosis, and 11 (2.90%) to HCC during the observation period.
Donors with HCV 
infection 
n=402
Death from 
liver dieases 
n=15
Death from other 
causes 
n=16 
Death from 
cirrhosis 
n=5
Follow up in May 2010
n=348 
Death from 
HCC in 
cirrhosis 
n=10
N=19 
HCV spontaneous 
clearance 
n=74 
Anti-HCV 
S/CO<5 
n=10 
Anti-HCV 
S/CO 5 
n=64 
Chronic HCV 
infection  
n=274 
Cirrhosis
n=22 
Chronic 
hepatitis  
n=249 
Live stiffness 
measurement 
n=183 
HCC in 
cirrhosis 
n=1 
Follow up
n=379
Loss of follow up 
n=23 
Figure 1 Summary of the outcome of the
402 donors recruited.
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The rate of chronicity in these 379 donors group was 79.68%,
and the rate of viral spontaneous clearance was 20.32% (77/379,
95% confidence interval [CI]: 16.27–24.37%).
Of 348 plasma donors studied in May 2010, 156 were male and
192 were female, with a mean age of 53.7 7.4 years. The char-
acteristics of the 348 donors are shown in Table 1. Five patients
had co-infection with HBV (HBsAg positive) when re-evaluated in
2008 using the Abbott kit. All 348 donors were serum anti-HIV
negative. The age at time of HCV infection was 28.1 7.3 years,
and the infection duration was 25.2  3.4 years (range:
14–35 years). Of the 348 donors, 2.87% (10/348, 95% CI: 1.12–
4.62%) were serum anti-HCV signal-to-cutoff ratio (S/CO) < 5,
18.39% (64/348, 95% CI: 14.32–22.46%) were serum anti-HCV
S/CO  5 and HCV-RNA negative, and 78.74% (274/348, 95%
CI: 74.44–83.04%) were anti-HCV S/CO  5 and HCV-RNA
positive. Ultrasonography evaluation showed 6.61% (95% CI:
4.00–9.22%) with liver cirrhosis, 0.29% (95% CI: -0.27% to
0.85%) with HCC, and 19.25% (95% CI: 15.11–23.39%) with
steatohepatitis.
Relation of live function abnormality to HCV
viremia
Of the 348 donors, the rate of ALT and/or AST abnormalities in the
group of anti-HCV S/CO 5 and HCV-RNA positive was 56.57%
(155/274, 95% CI: 50.70–62.44%), anti-HCV S/CO  5 and
HCV-RNA negative was 3.13% (2/64, 95% CI: -1.14% to 7.40%),
while that in the anti-HCV group S/CO < 5 was zero. The abnor-
mal rate of ALT and/or AST in the HCV-RNA positive group was
significantly higher than that in the negative group (57.57% vs
2.70%, P < 0.01; OR = 44.85, 95% CI: 10.79–186.51%). The
average level of ALT, AST, and g-GT in the positive group of
HCV-RNA was significantly higher than that in the negative group
(P < 0.01) (Table 2).
Impact of sex on the outcome of HCV
infection
Of the 379 donors, 145 male cases and 157 female cases were
detectable for HCV-RNA. The rate of viral spontaneous clearance
was 13.69% in the male group and 25.59% in the female group. A
significant difference was found between them (OR = 2.17, 95%
CI: 1.27–3.71). There were 27 cases of liver cirrhosis were found:
18 male cases and nine female cases. There were also 1l cases of
HCC: seven male cases and four female cases.
Of the 348 donors, the mean values of ALT and AST were
significantly higher in the male donors than the female donors
(Table 3, P < 0.01). The rate of ALT and/or AST abnormalities was
significantly higher in the male donors than in the female donors
(Table 3, P < 0.01).
Impact of alcohol intake on the outcome of
HCV infection
Seventy four of 348 cases had an alcohol intake of more than 40 g
every day. In the HCV-RNA-negative group, there were 16 cases
(16/74, 21.62%) of alcohol intake. In the HCV-RNA-positive
group, there were 58 cases (58/274, 21.16%) of alcohol intake. No
significant difference was found between alcohol intake and HCV
spontaneous clearance. Of the 22 liver cirrhosis donors, 10
(45.45%; OR = 3.92, 95% CI: 1.63–9.41) had an alcohol intake if
more than 40 g per day.
HCV genotyping was not related to the
outcome of HCV infection
Of the 302 HCV-RNA-positive donors, 84.11% (254/302),
12.91% (39/302), and 2.98% (9/302) were HCV genotype 1b, 2a,
and 1b/2a, respectively. Of the 38 liver cirrhosis donors, 32 were
HCV genotype 1b, five were 2a, and one was 1b/2a. No significant
difference was found between HCV genotyping and outcome of
HCV infection (P > 0.05).
No correlation between age at contamination
and HCV spontaneous clearance rate and liver
cirrhosis incidence
We divided the 379 donors into two groups, according to the age of
infection:  30 years and > 30 years (Table 4). The rate of spon-
taneous viral clearance in the two groups was 19.46% and 21.52%.
There was no significant difference between different ages at
infection. The rate of liver cirrhosis incidence in the two groups
Table 1 Demographic, clinical, and biological characteristics of blood
donors
n (%) or mean  SE
Sex (male/female) 156/192
Mean age (years) 53.7  7.4
Mean age at infection (years) 28.1  7.3
Mean infection duration (years) 25.2  3.4
Alcohol consumption >40 g/day 74 (21.26%)
Male 57 (36.54%)
Female 17 (8.85%)
Platelet count (109/L) 209.3  66.8
ALT (IU/L) 45.8  42.4
AST (IU/L) 44.8  33.1
GGT (IU/L) 40.6  75.8
Data were expressed as n (%) or mean  SD. ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; GGT, c-glutamyl transpepti-
dase.
Table 2 Comparison of biochemistry between patients with or without
hepatitis C virus (HCV) spontaneous clearance
HCV-RNA positive HCV-RNA negative P-value
Cases (n) 274 74
ALT (IU/L) 53.50  44.57 17.22  8.43 < 0.01
AST (IU/L) 50.74  34.78 22.65  6.30 < 0.01
ALP (IU/L) 90.04  29.20 85.85  25.48 > 0.05
g-GT (IU/L) 45.82  83.93 21.05  21.32 < 0.01
Tbil (mmol/L) 19.15  7.68 16.78  6.76 > 0.05
Glucose (mmol/L) 5.26  2.07 5.31  1.65 > 0.05
ALB (G/L) 46.53  3.18 47.64  2.44 > 0.05
Data were expressed as n or mean  standard deviation. ALB, albumin;
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspar-
tate aminotransferase; g-GT, g-glutamyltransferase; Tbil, total bilirubin.
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was 8.14% and 12.66%. There was also no significant difference
between age at contamination and liver cirrhosis incidence.
Multivariate analysis of factors associated with
the outcome of HCV infection
The multivariate analysis included the following variables: sex and
alcohol consumption, which were found to be significant in the
univariate analysis. Sex had an independent effect on spontaneous
HCV clearance; the odds ratio for women to clear HCV infection
in the multivariate model for all donors was 1.98 (95% CI: 1.12–
3.34) when compared to men.
Liver stiffness measure
Of the 177 donors, FS detection (Table 5) showed 89 donors with
liver stiffness < 7.2 kPa, 31 donors with 7.2–9.5 kPa, 25 donors
with 9.6–12.5 kPa, and 30 donors with > 12.5 kPa. The average
level of ALT and AST in the liver stiffness > 12.5 kPa group was
significantly higher than that in the liver stiffness  12.5 kPa
group (P < 0.01). The average platelet level (PLT) in the liver
stiffness > 12.5 kPa group was significantly lower than that in the
liver stiffness  12.5 kPa group (P < 0.01). The donors with liver
stiffness > 9.6 kPa were all HCV-RNA positive. No significant
difference of HCV-RNA load and age at infection was found
between different liver stiffness groups. In the HCV spontaneous
clearance group, the liver stiffness was 5.30 1.72 kPa, and in the
HCV chronic infection group, the liver stiffness were
11.32  9.76 kPa (P < 0.01 vs the HCV spontaneous clearance
group).
Discussion
The anti-HCV epidemic rate is 3.2% in the Chinese population,
and it is estimated that 40 million people are infected.17 Through
the screening of blood donors since 1990s, the incidence of HCV
has decreased, but some patients have progressed to chronic hepa-
titis, liver cirrhosis, and HCC. In the past 10 years, the incidence of
HCV infection reported by the Center for Disease Control and
Prevention of China has increased evidently.18 Although there are
some reports on the natural history of HCV infection in Western
countries,5,7,19,20 few similar studies have been carried out in China,
so it is necessary to observe the outcome of HCV infection in
China.
In our study, all of the donors were farmers, and were not
covered by social medical insurance; they needed to pay for the
medical therapy themselves, and could not afford standard antivi-
rus therapy, so these donors had not received treatment for hepa-
titis C. For the long-term follow up, 10.03% of patients were found
to have cirrhosis, and 2.90% had HCC; the HCV-related mortality
Table 3 Comparison of hepatitis C virus (HCV)-RNA undetectable rate, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)
between males and females
Males Females OR OR 95% CI
Cases (n) 168 211
HCV-RNA negative 23 54
HCV-RNA undetectable rate 13.69% 25.59%* 2.17 1.27–3.71
Cases followed in 2010 (n) 156 192
ALT 54.88  44.13 38.40  39.57*
AST 50.03  31.97 40.49  33.38*
ALT/AST normalities rate 42.31% 65.10%* 2.54 1.65–3.93
*P < 0.01 versus the male group. Data were expressed as n (%) or mean  standard deviation. CI, confidence intervals; OR, odds ratio.
Table 4 Comparison of hepatitis C virus (HCV)-RNA-negative rate 14–35 years after infection among different ages
Age at infection Cases HCV-RNA positive HCV-RNA negative HCV-RNA-negative rate OR OR 95% CI
All 379 302 77 20.32%
 30 221 178 43 19.46% 1
> 30 158 124 34 21.52% 1.14 0.69–1.88
c2 = 0.2420, P = 0.6228. CI, confidence intervals; OR, odds ratio.
Table 5 Comparison of hepatitis C virus (HCV)-RNA, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), and platelet
between different liver stiffness patients
FibroScan n HCV-RNA log10 IU/mL ALT AST ALB PLT
< 7.2 kPa 89 6.40  0.88 34.3  28.9 34.2  20.4 46.9  2.4 219.4  59.9
7.2–9.5 kPa 31 5.89  1.50 41.5  30.7 38.7  21.5 47.2  2.5 204.9  48.9
9.6–12.5 kPa 25 5.99  0.94 52.8  39.7 52.2  29.3 46.7  2.7 205.8  68.4
> 12.5 kPa 30 6.20  0.74 81.6  63.9* 81.0  65.2* 44.4  4.0 161.5  65.1*
*P < 0.01 vs the liver stiffness  12.5 kPa group. Data were expressed as n (%) or mean  SD.
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was 3.96%. Although we found a pattern of more progressive
disease more than 20 years after infection, the overall rate of
HCV-related liver disease was relatively low in our study. The
benign course of our study could be explained by the mode of
contamination and the age of the patients at contamination (mean
age: 28.2  7.2 years). Patients infected at a young age are at
lower risk for progressive liver disease.8 The mode of HCV trans-
mission offers a particularly useful insight into the prognosis. For
example, in a German study of 1833 women infected with HCV-
contaminated RH0 (D) immunoglobulin, none of these women
were found to have chronic active hepatitis or cirrhosis 15 years
later. After 25 years’ follow up, cirrhosis was found in only 0.5%
of cases.5 This result is similar to another study of an outbreak of
HCV infection from contaminated anti-D immunoglobulin.7 In
other modes of contamination, such as blood transfusions, there is
great variability in the long-term outcome of HCV infection. A
group from Australia reviewed existing, published data, and based
on an analysis of 57 studies, concluded that after about 20 years,
cirrhosis had developed in 24% (11–37%) of people infected
through blood transfusions, 22% (18–26%) who were evaluated at
a tertiary care liver clinic, 7% (4–10%) of community-based
cohort studies, and in 4% (1–7%) of blood donors.21
During our investigation, the infection was spontaneously
resolved in some cases. The rate of spontaneous resolution in the
present study was 20.32%; 13.69% in the male group and 25.59%
in the female group. The mean level of ALT, AST, and g- GT in
HCV-RNA-positive cases was significantly higher than that in
negative cases. Regarding sex, there is evidence that the rate of
liver disease progression is lower in women than in men.22 Our
study indicated that the viral spontaneous clearing was higher in
women than in men. The cases who progressed to liver cirrhosis in
our study were mostly males. The rate of ALT and/or AST abnor-
malities in males was significantly higher than that in females,
indicating that males might be more prone to serious liver disease
than females.
The role of alcohol consumption has been established as a daily
intake greater than 40 or 50 g per day.23,24 In the present study,
there was no correlation between the viral spontaneous clearance
with alcohol consumption; however, liver cirrhosis incidence was
related to an alcohol intake of more than 40 g every day. Although
alcohol abuse has been clearly shown to increase the severity of
hepatitis C, with more rapid progression to cirrhosis and HCC,
these effects relate mainly to patients with quite high daily alcohol
intake.25,26 Much less is known on whether a light or moderate
amount of alcohol might also exert a negative influence on HCV.27
Alcohol consumption is difficult to quantify, and conclusions must
be prudent. However, it seems that the influence of alcohol is
independent of other factors, weaker than the influence of age, and
is exerted only at toxic levels of intake.
As described previously,28,29 age appears to be an important
determinant of progression. The data suggest that the younger the
age at infection, the lower the rate of progression. In the present
study, no difference was found in the rate of viral resolution in the
different age groups, which is consistent with a previous report.30
In our study cohort, the age at infection for most donors might
possibly have been relatively younger.
Transient elastography is painless, rapid (< 5 min), and easy to
perform at the bedside or at the outpatient clinic. Importantly, the
results are immediately available and independent from the opera-
tor. In the HCV spontaneous clearance group, the liver stiffness
was 5.30  1.72 kPa, and in the HCV chronic infection group, the
liver stiffness was 11.32 9.76 kPa. There were correlations
between ALT, AST, and PLT levels with liver stiffness: 30 donors
(16.95%) had liver stiffness >12.5 kPa. Severe hepatic inflamma-
tion can affect the liver stiffness findings, and thus, care is required
when assessing fibrosis stage using liver stiffness measurements in
patients with severe inflammation.31
In the present study, 10 donors were serum anti-HCV S/CO <5.
Our finding is similar to some previous studies, in that seroclear-
ance of anti-HCV might be observed in immunocompetent HCV-
infected individuals after a self-resolved infection.32,33 Prevalence
studies are most often based on serological testing. Therefore,
further studies should take into account the occurrence of sero-
clearance of anti-HCV after a past and self-resolved infection.
The silent onset of the acute phase of hepatitis C infection,
coupled with the frequent lack of symptoms during the early stages
of chronic infection, has meant that the natural history of hepatitis
C virus infection has been very difficult to assess. The optimal
study to assess progression is one in which the onset of infection
is precisely defined; the infection emanates from a single, identi-
fied source; the case ascertainment is high; the study population is
large; and where follow up is prospective, comprehensive, and of
long duration.34Such an idealized combination of study parameters
is very difficult to achieve.
Five patients had co-infection with HBV when re-evaluated in
2008 using the Abbott kit, but none of these patients were HBV
infected at the start of follow up. During follow up, none of the
donors donated plasma, perhaps because the sensitivity of the
Abbott kit is higher than the reagent used in 1991 or 1998.
Our retrospective, progressive study offered the possibility of
investigating the long-term outcome of plasma donors with HCV
infection. Unfortunately, the serological testing for anti-HCV was
not available before 1990 in China; also, the samples were not to
be collected during outbreaks between 1972 and 1990 in these
donors for anti-HCV and HCV-RNA testing. Thus, it was impos-
sible to define the accurate time of the onset of infection. The time
of the onset of acute hepatitis non-A, non-B is known by the first
time of ALT elevation. In donors with normal ALT levels, the
lattermost plasma donation time was considered as onset of infec-
tion. When serological testing became available, all infected
donors in our study tested positive for anti-HCV in 1991 or 1998.
The results of our follow up, obtained in this large cohort of
patients with predominantly chronic hepatitis C virus genotype 1b
infection, showed a slowly-progressive liver disease.
In conclusion, this area has a high rate of chronicity in HCV
infection due to plasma donation. Our study supports earlier data
that although there is no significant mortality in the first 20 years
after infection, later follow up shows that both morbidity and
mortality increase. These data underline the progressive nature of
chronic HCV infection due to plasma donation, and the need to
identify and treat infected patients.
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